The Food and Drug Administration has given the green light to Moderna’s innovative mRNA flu vaccine, named mFLUSIVA, enhancing the options available to older Americans. Set to roll out in time for the 2026-2027 flu season, this new vaccine targets individuals aged 50 and above.
The Impact of mFLUSIVA
Flu continues to pose a significant threat to public health, especially among seniors. “Flu remains a considerable public health challenge, and mFLUSIVA provides an important new option for America’s seniors,” stated Stéphane Bancel, the CEO of Moderna. This approval highlights the potential of mRNA technology not just in the fight against COVID-19, but also in combating seasonal illnesses.
In clinical trials involving participants aged 50 to 64, mFLUSIVA demonstrated a 27% reduction in confirmed flu cases compared to traditional vaccines. While the safety profile was comparable to existing options, it’s worth noting that participants receiving the mRNA vaccine reported slightly more side effects; however, these were mainly mild and lasted two days or less.
Future Considerations and Regulatory Insights
For individuals aged 65 and older, a high-dose flu vaccine remains the current recommendation. Moderna has committed to tracking the performance of mFLUSIVA this winter and plans to submit findings to the FDA to determine if it should maintain its approval for this age group.
This recent approval comes after a unique journey; earlier this year, the FDA refrained from reviewing Moderna’s application, only to reverse its decision once the company agreed to conduct additional research post-launch.
Health Secretary Robert F. Kennedy Jr. has expressed skepticism regarding the mRNA vaccine platform. Previously, funding aimed at mRNA vaccine development saw a setback, with Kennedy advocating for investments in alternatives that adapt better to virus mutations, despite widespread support for the safety and efficacy of mRNA vaccines among medical experts.
Vaccine specialists highlight that this mRNA approach would not only expedite vaccine production but also ensure that shots align more closely with the circulating strains of flu viruses. The CDC currently recommends that everyone over six months of age receive an annual flu shot, ideally before the end of October. This crucial vaccination helps mitigate the risk of severe illness, including hospitalization and mortality.
